In the past decade, progress in the treatment of disseminated human cancers has been marginal, with a few notable exceptions, despite new chemotherapeutic agents and re®ned radiotherapy and surgical techniques. There is an obvious need for mechanistically novel therapies to complement established treatments and thus improve cancer care. Advances in the understanding of the molecular basis of neoplastic transformation and host±tumour relationships have presented a good opportunity not only to develop new anticancer strategies but also to translate this basic research into clinical practiceÐ`from bench to bedside'. The generation of high-ef®ciency gene transfer systems capable of modifying human cancers has led to genetic and immunological therapy as two powerful strategies in the rational design of cancer treatments. This paper highlights scienti®c and clinical developments in the genetic and immunological therapy of cancer presented at a Royal Society of Medicine symposium in June 1999.
IMMUNOTHERAPY

How does the immune system function?
The immune response system consists of an innate (nonadaptive) component which includes effector cells such as macrophages and natural killer (NK) cells and an adaptive component involving antigen-speci®c B and T lymphocytes. Both B and T cells clonally express antigen-speci®c receptors that are generated during lymphocyte differentiation by somatic gene rearrangement. Since this gene rearrangement will, by chance, also give rise to cells expressing self-reactive receptors, it is followed by selection and clonal deletion to remove strongly autoreactive lymphocytes. For T lymphocytes, this takes place in the thymus, where clones with receptors of useless or deleterious speci®city are removed by apoptosis and those with useful speci®cities are positively selected. B lymphocyte receptors are expressed initially at the cell surface but, following signals generated by exposure to antigens (e.g. infections), antigen-speci®c B cells mature further and secrete their receptors, which then circulate in the body as antibodies. The signals to which antigen-speci®c B cells respond must include those from T cells. The antigen-speci®c receptors on T lymphocytes are expressed on the cell surface only and are not shed as soluble molecules. Interaction of T cells with either B cells or antigen presenting cells (APCs, e.g. dendritic cells, macrophages) makes use of membrane-bound receptors on T cells. The antigen-speci®c receptor recognizes peptide fragments of antigen presented by cell surface transmembrane glycoproteins encoded by the major histocompatibility complex (MHC) and HLA class I and II molecules. In this way, all T cell recognition of foreign, non-self, antigens involves corecognition of self-MHC molecules, a phenomenon known as MHC restriction. This was ®rst discovered for T cell responses to viruses such as cytomegalovirus (CMV) and the in¯uenza A virus, but is also true for T cell recognition of endogenous epitopes such as autoantigens and tumour antigens. We are only just beginning to understand the three-dimensional dynamicsÐthe spatial and temporal regulationÐthat determine the ®nal immune response.
Tumour antigens
Certain tumour antigens can be recognized and targeted by the immune system. This property may be due to overexpression by the tumour tissue. Some of these antigens can be detected in normal tissue. The tumour antigens targeted by T cells are proteins that are processed intracellularly and presented as short peptide fragments bound in the groove of the tumour MHC class I molecule to be recognized by CD8 + cytotoxic T lymphocytes (CTLS)Ð see Figure 1 . The mere presence of a tumour antigen is not suf®cient to trigger an immune response. Co-stimulatory molecules such as B7.1 are required. Once antigen-speci®c T cells are stimulated, they are capable of recognizing and destroying the tumour. The conditions needed for the activation of antigen-speci®c T cells are stringent, but are open to genetic manipulation of target tumour cells and T cells.
Primary tumours may not induce tumour-speci®c T cell responses because of (i) defective antigen presentation to the immune system and (ii) defective activation of T cell effector cells. Given this blunting and inef®ciency of the immune response to tumours (tolerance), strategies for augmenting the anti-tumour response have been investigated.
These include both local antitumour effects and the enhancement of systemic antitumour immunity. Modalities for inducing host immunity against tumours (Table 1 ) are now entering clinical trials.
Thus, the aim of anticancer immunotherapy is to generate a local immune response and systemic antitumour immune memory to destroy metastases.
Adoptive cytotoxic T lymphocyte therapy
Adoptive immunotherapy for human tumours is the transfer of lymphocytes to mediate an effector function against the tumour. The speci®city of cytotoxic T cells has made this population of cells an attractive clinical goal. Data from several trials indicate that adoptively transferred T cells can persist for long durations 1 . Memory is manifested by the clonal survival of these effector cells.
In persistent virus infections where viral replication is controlled by speci®c cytotoxic T lymphocytes (CTLs), such as Epstein±Barr virus (EBV) and cytomegalovirus, adoptive transfer of CTLs generated from the original marrow donor to patients immunosuppressed following bone marrow transplantation has proved bene®cial in reducing the incidence of serious viral disease 2 . Modest doses of T cells are an effective treatment for EBVassociated lymphoma, with complete remissions in most patients 3 .
Human immunode®ciency virus (HIV)-speci®c CTLs are also thought to mediate control of viral replication during HIV infection. The development of soluble MHC-peptide tetrameric complexes as a means of identifying and quantifying CTLs with speci®city for that epitope has proved a major advance for studying the dynamics and phenotype of antigen-speci®c T cells. Rowland Jones et al. have used an A2 tetramer complexed with an HIV peptide to track the fate in vivo of HIV-speci®c CTL clones which had been expanded to large numbers (410 9 ) in vitro and infused into an HIV-infected patient with uncontrolled HIV replication. By double staining CD8+ T cells with tetramer and annexin-V as a marker of apoptosis, they found that more than 90% of the infused CTLs were undergoing apoptosis within 24 hours 4 . Nonetheless, limited T cell help' may be available in HIV patients. Further trials of adoptive transfer of CTLs in cancer therapy, therefore, should take into account the susceptibility of infused cells to in-vivo apoptosis.
GENE THERAPY
Gene therapy is the introduction of genetic material into a patient's tissues with the aim of therapeutic bene®t. Several strategies to exploit gene transferÐas a tool to enhance tumour chemosensitivity, target speci®c molecular defects intrinsic to cancer cells and augment tumour immunogeni-cityÐare underway. Targeting of gene therapy strategies that rely on in-situ gene modi®cations can theoretically be accomplished at the gene entry or gene expression level. Regulation of gene transcription is made possible through the incorporation of cell-speci®c promoters of enhancer sequences within the transgene construct.
Gene delivery systems are crucial to the success of gene transfer in the modi®cation of tumour cells. Several gene transfer systems have been designed, and one of the leading gene therapy vectors is adenovirus (Ad), because of its
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unrivalled capacity to deliver a transgene ef®ciently to a high proportion of target cells in vitro, ex vivo and in vivo.
First generation replication-de®cient Ad vectors, based on E1 gene deletion mutants, can induce high-level transient gene expression in many cell types. A considerable research effort is concentrated on optimizing vectors for speci®c clinical applications. The safety and performance of Ad vectors have been enhanced by the deletion of additional genes from the virus. Indeed, vectors have been generated in which all Ad protein-coding sequences have been removed, although propagation of these`gutless' vectors is dependent on coinfection with an Ad helper virus. It is often advantageous to be able to restrict transgene expression to the target cell population. The Ad particle can be manipulated so that it no longer recognizes its natural receptor but is retargeted to a ligand speci®c to a target cell. High levels of expression can be achieved by use of a strong constitutive viral promoter, while tumour-speci®c promoters can be exploited to restrict expression to malignant cells. Ad vectors have been developed to deliver not just a therapeutic gene but also an entire vector systemÐmost notably the adenovirus±retrovirus chimeric vector system.
Strategies to enhance tumour chemosensitivity
In the approach known as suicide gene therapy, tumours are transduced with prodrug-converting enzymes and then exposed to agents that, once enzymatically cleaved, are converted into a cytotoxic species. While death of bystander tumour cells occurs after local release of active drug, in¯ammation in response to the dying cells has been proposed to result in systemic immunity 5 . Gene prodrug activation therapy enables a choice not only in the vector, e.g. virally directed prodrug enzyme therapy, but also in the prodrug, the activating enzyme and the target cells. An example is the prodrug CB 1954 (5-[aziridin-1-yl]-2,4dinitrobenzamide)/Escherichia coli nitroreductase system illustrated in Figure 2 . This generates a potent bifunctional alkylating agent that crosslinks DNA and is similarly toxic to non-replicating cells. The prototype of this approach, however, is the intracellular phosphorylation of ganciclovir by the herpes simplex virus thymidine kinase gene product (HSV-TK). Several clinical trials have been initiated but none has yet been fully reported 6 . Drug resistance gene therapy has utility for patients who are undergoing myelosuppressive chemotherapy. This not only protects the marrow stem cells but also provides selection in favour of transduced cells in circumstances where it is desirable to replace the marrow with a new population of cells. Retroviruses seem to be the most appropriate vector for haematopoietic stem gene transfer because of their ability to integrate the gene into the DNA of progenitor cells to improve the possibility of long-term expression in progeny. The three drug resistance genes used most frequently in drug resistance transfer are multi-drug resistance gene-1, dihydrofolate reductase and methylguanine-DNA-methyltransferase. Each has the potential to transmit drug resistance to a range of conventional cytotoxic drugs and to result in selective survival of progenitors, but unfortunately no transduction has yet been documented in clinical trials.
Strategies to target speci®c molecular defects intrinsic to cancer cells
Malignant phenotype reversal aims to replace the defective gene by transfection of the wild-type (WT) gene into tumour cells and thus restore normal function. That a single gene will be suf®cient to reverse the malignant phenotype is highly unlikely. In-vivo studies have demonstrated that WT p53 has an effect not only on the primary tumour but also on the relapse and metastases of these tumours 7 . A phase I trial that used retroviral-mediated gene transfer to introduce WT p53 into non-small-cell lung carcinoma cells showed antitumour responses in injected nodules 8 .
Oncogene expression reversal is a second possible approach. The identi®cation and sequencing of malignant phenotypes from altered or overexpressed oncogenes has led to the development of antisense products e.g. to c-fos, cmyc and k-ras.
Strategies to augment the immune responseÐ immunogenetic therapy
One potential application for gene therapy has been the transfer of genes for the purpose of inducing immune responses. Genes can be transferred by viral vectors either to cultured tumour cells in vitro that can be returned to the patient as a cancer`vaccine' or directly to tumour cells in vivo.
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V o l u m e 9 3 J a n u a r y 2 0 0 0 Figure 2 VDEPT paradigm: Prodrug CB 1954 E. coli nitroreductase system. For cancer patients with peritoneal carcinomatosis, the virus is delivered intraperitoneally to the tumour cells before pro-drug administration. This is ef®ciently converted into its active form only in the tumour cells, which already contain the virusencoded conversion enzyme
The goal of anticancer vaccination is the induction of protective immunity against malignancy. With increased understanding of the mechanisms underlying the generation and maintenance of immune responses, a more rational approach to the development of cancer vaccines has emerged which takes into account the need to overcome immunological tolerance and to elicit appropriate cellmediated responses. Thus, a major focus of interest is the identi®cation of tumour antigens and the targeting of these antigens to bone-marrow-derived antigen-presenting cells. Mirroring the development of antivirus vaccines, the ®eld of cancer vaccines has moved from the use of unmodi®ed tumour cells through the genetic incorporation of cytokine and costimulatory molecules as adjuvants to, more recently, the administration of tumour antigens. A more detailed knowledge of molecular immunology has resulted in the use of peptide epitopes from tumour antigens as immunogens, as well as recombinant viral and bacterial vectors to deliver these antigens directly to antigen-presenting cells. These major approaches to immunogenetic therapy are detailed below.
Cytokine or costimulatory molecule gene modi®ed tumour cells and de®ned tumour antigens
One method has been to test the relative vaccination potential of irradiated tumour cells engineered to secrete various immunostimulatory gene products e.g. granulocytemacrophage colony stimulating factor (GM-CSF) 9 , B7.1, IL 12, IL 2 or an allogeneic MHC complex. An advantage of cytokine gene transfer into a tumour cell vaccine is that the paracrine secretion of cytokines may closely resemble the physiological mode of cytokine delivery to its target, leading to activation of CTLs in the absence of CD4+T helper cells 10 .
Live attenuated virus as vectors
Live attenuated viruses can be used as vaccines to deliver newly synthesized antigen to the class I processing pathway and induce a CTL response. One gene-based approach is to use vaccinia virus. The Laboratory of Tumor Immunology and Biology at the National Cancer Institute, Bethesda, has used a recombinant vaccinia virus that expresses the carcinoembryonic antigen (CEA) gene (rV-CEA). In an early clinical trial, induction of a T-cell response towards CEA was seen 11 .
Autologous tumour cells
Autologous tumour cells can be used as the foundation of patient-speci®c vaccines. This is technically more ambitious. Vaccination with irradiated, autologous melanoma cells engineered to secrete interferon-g have elicited minor clinical responses in patients with metastatic disease 12 .
Cationic liposomes
Cationic liposomes that encapsulate DNA expression plasmids which encode allogeneic MHC molecules have been used to generate tumour vaccines in situ. Tumour regression and responses at distant sites have been reported in metastatic melanoma patients 13 .
Clearly, the context in which the immune system perceives' tumour cells is of great importance to its subsequent reaction to them. One approach is to orchestrate an appropriate environment within tumours, using gene transfer strategies to achieve the correct sequence of immunological activation events which will lead to the breaking of tolerance against the patient's own tumour cells. The ®rst goal is to create a highly immunostimulatory intratumoral environment into which appropriate subsets of immune cells can be recruitedÐfor example, by gene transfer of the cytokine GM-CSF. Following adequate recruitment, it is then important to cause cell death in such a way that antigen-presenting cells can be stimulated to take up released tumour antigens. For this to occur optimally, the tumour killing should be induced in physiologically`dangerous' ways such that immunological activation signals, e.g. inducible heat shock proteins (hsps), are induced; tumour immunogenicity is determined by the mechanism of cell death via the induction of heat shock protein, and increased levels of hsp, induced by non-apoptotic killing, may provide an immunostimulatory signal in vivo which breaks tolerance to tumour antigens 14 . Thereafter, the antigen-presenting cell should be able to mature and traf®c to other sites, principally the lymph nodes, which can be achieved by inducing expression of genes such as CD4OL.
The future development of cancer immunogenetic therapy depends on the identi®cation and ef®cient delivery of immunodominant tumour antigens as well as the use of whole tumour cellsÐe.g. the introduction of tumour-cellderived mRNA into dendritic cells, which allows the display of a broad repertoire of potential antigens. In addition, clinical trials that incorporate appropriate immunological endpoints are required.
Clinical trial design for gene therapies
The above discussion indicates multiple possible approaches to the gene therapy of cancer, and more than 150 clinical trials have been started, predominantly in the USA. The clinical methodology in phase 1 trials of novel gene therapeutic agents, which should be hypothesis testing and designed to provide as much feedback as possible to the basic scientists involved, is crucial. In the UK our Birmingham group now has permission to perform a phase 1 trial of adenoviral-CEA promoter driven nitroimidazole reductase V o l u m e 9 3 J a n u a r y 2 0 0 0 ( Figure 2 ). Patients with peritoneal carcinomatosis from CEA-positive tumours with ascites are being recruited. After drainage of ascitic¯uid, a peritoneal catheter will be used to administer the virus in 1 litre of dialysate. Samples of peritoneal¯uid and blood will be taken at regular intervals thereafter and, by immunocytochemical and molecular biological techniques, we shall estimate the fraction of cancer cells infected by the virus, the degree of expression of the therapeutic enzyme, the ®delity of the tumour speci®c promoter, the extent of virus escape into the bloodstream and its excretion pathway and immunological antiviral responses. This information will serve in the design of second and third generation viral gene therapy vectors.
CONCLUSION
Patient care has yet to be substantially altered by gene therapy or immunotherapy but we believe that, in the next decade, these will become integral components of a multidisciplinary approach to treatment of malignant disease.
